YSCH-01 for Recurrent or Progressive Glioblastoma
A Single-Arm, Open-Label, Dose-Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YSCH-01 in Subjects With Recurrent or Progressive Glioblastoma
This is an open-label dose-escalation and dose-expansion study that plans to enroll 16 to 32 adult participants with recurrent or progressive glioblastoma. Participants will be assigned to different dose groups. This study consists of two parts, namely the dose escalation stage and the dose expansion stage. The study aims to determine the safety and tolerability of the oncolytic adenovirus YSCH-01 in adult participants with recurrent or progressive glioblastoma.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Yiyan Xu
- 电话号码:+86-021-60975992
- 邮箱:xuyiyan@yuansongbio.com
学习地点
-
-
-
Shanghai、中国、200040
- Huashan Hospital
-
接触:
- Jiang Shan
- 电话号码:+86-13661519863
- 邮箱:jsscosmos@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Subjects who are willing to sign the informed consent form (ICF), able to understand the study, and willing to follow the protocol and complete all the study procedures;
-
Male or female aged ≥ 18 and ≤ 75 years;
-
Disease status: Subjects with an initial glioblastoma histopathologically confirmed in accordance with the 2021 WHO Classification of Tumors of the Central Nervous System, who have developed disease recurrence or progression following standard of care. The standard of care consists of surgical resection, chemotherapy and/or radiotherapy. For subjects with known specific molecular alterations (e.g., NTRK fusions), prior standard targeted therapy recommended by the latest local guidelines is required, except for subjects for whom the investigator judges standard of care to be inapplicable, of limited benefit, or intolerable; the rationale for intolerance shall be documented.
-
Patients with at least one measurable lesion (≥10 mm in both perpendicular diameters as per RANO 2.0 criteria) within 4 weeks before YSCH-01 treatment;
-
Subjects with a karnofsky performance status (KPS) score of ≥70 and the expected survival period is ≥ 3 months;
-
Subjects with adequate organ and hematopoietic function:
Hematological function: absolute neutrophil count (ANC) ≥1.0×10⁹/L, hemoglobin (HGB) ≥90 g/L, platelet count (PLT#) ≥100×10⁹/L. No blood transfusion, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human erythropoietin, recombinant human thrombopoietin, platelet receptor agonists, recombinant human interleukin-11, or other supportive treatments within 14 days prior to screening; Liver function: total bilirubin (TBIL) ≤2×ULN, except for subjects with Gilbert's syndrome; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN (≤5×ULN in the presence of liver metastases); Renal function: serum creatinine (Cr) ≤1.5×ULN; Coagulation function: in the absence of anticoagulant therapy, prothrombin time (PT), activated partial thromboplastin time (APTT), or international normalized ratio (INR) ≤1.5×ULN
-
Male subjects of reproductive potential and female subjects of childbearing potential must agree to use reliable contraceptive methods (hormonal contraception, barrier methods, or abstinence) during the study and for at least 6 months after the last dose of YSCH-01; female subjects of childbearing potential must have a negative blood or urine pregnancy test within 7 days prior to enrollment.
Exclusion Criteria:
-
Subjects with a known severe allergy to any component of the investigational drug, Ommaya reservoir, or other oncolytic virus therapies;
-
Pregnant or breast-feeding women;
-
Subjects with positive results for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), and a hepatitis B virus deoxyribonucleic acid (HBV-DNA) level higher than the lower limit of detection; subjects with a positive result for hepatitis C virus (HCV) antibody and a hepatitis C virus ribonucleic acid (HCV-RNA) level higher than the lower limit of detection; subjects with a positive result for human immunodeficiency virus (HIV) antibody;
-
Subjects who received chemotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor drugs within 4 weeks prior to the first dose; Chinese herbal medicines or Chinese patent medicines with anti-tumor indications within 2 weeks; Subjects who received radiotherapy within 4 weeks days prior to the first dose;
-
Subjects with known or suspected active autoimmune diseases, including but not limited to Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.;
-
Subjects who require systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days prior to the first dose or during the study, with the following exceptions:
Adrenaline replacement steroids (prednisone ≤10 mg/day or equivalent); Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids; Prophylactic short-term (≤7 days) use of corticosteroids (e.g., allergy to contrast media) or for the treatment of non-autoimmune diseases (e.g., delayed hypersensitivity reactions caused by contact allergens).
-
Subjects with tumor lesions in critical anatomic areas (e.g., ventricular invasion or proximity to the brainstem and spinal cord, or the posterior fossa);
-
Subjects with clinically significant increased intracranial pressure (e.g., impending brain herniation or requirement for immediate palliative treatment) or uncontrolled seizures;
-
Subjects with poorly controlled mental disorders, or who, in the investigator's opinion, have a medical history or mental state that may increase the risks associated with study participation or investigational drug administration, or that may interfere with the study results;
-
Subjects with toxicity and side effects caused by previous treatment that have not recovered to Grade ≤1 (per CTCAE V6.0); except for alopecia and other tolerable events judged by the investigator;
-
Presence of cardiovascular disease or conditions including any of the following:
There are severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, etc.; At rest, the average QTcF obtained from 3 12-lead electrocardiogram examinations is greater than 450ms; Within 6 months before the first administration, acute coronary syndrome, congestive heart failure, stroke or other grade 3 or above cardiovascular events occurred; The New York Heart Association (NYHA) cardiac function classification is ≥ II grade or the left ventricular ejection fraction (LVEF) is less than 50%; Any factors that increase the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, long QT syndrome family history or a first-degree relative having sudden death before the age of 40 that cannot be explained, or using any known drugs that can prolong the QT interval.
-
Subjects who have participated in other interventional clinical studies within 1 month prior to study treatment;
-
Subjects who have previously received oncolytic virus therapy ;
-
Subjects with any contraindication for undergoing an Ommaya reservoir implantation procedure;
-
Subjects with any contraindication to magnetic resonance imaging (MRI), including pacemakers, epicardial pacing wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prostheses, or implants with potential magnetic properties;
-
Subjects with any serious or poorly controlled disease that, in the investigator's opinion, may increase the risks associated with study participation, investigational drug administration, or affect the subject's ability to receive the investigational drug, including but not limited to cardiovascular and cerebrovascular diseases, renal insufficiency, pulmonary embolism, coagulopathy, conditions requiring long-term anticoagulant therapy, active infection, and uncontrollable infection requiring long-term systemic treatment;
-
Subjects who have alcoholism, drug use or drug abuse;
-
Subjects with other malignant neoplasms within the past 3 years or currently, except for non-melanoma skin cancer and carcinoma in situ (e.g., cervical, bladder, and breast carcinoma in situ);
-
Subjects who receive live vaccines within 4 weeks prior to the first dose or planned during the study period;
-
Subjects with other conditions that, in the investigator's opinion, render the subject unsuitable for enrollment..
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose Escalation
Participants will receive the investigational product during the dose-escalation phase. The low-dose Dose cohort will enroll 3 participants initially. If no dose-limiting toxicities (DLTs) are observed in these 3 participants during the protocol-defined DLT observation period, enrollment at the higher dose level may proceed in accordance with the protocol-defined dose-escalation criteria. Safety and tolerability will be evaluated to determine the dose for further investigation. |
After being enrolled, the participants underwent tumor biopsy/ resection and then an Ommaya reservoir was implanted into the tumor. The participants would receive single-agent treatment with YSCH-01 every 3 weeks. YSCH-01 was administered within the tumor through the implanted Ommaya reservoir.
其他名称:
|
|
实验性的:Dose Expansion
Participants will receive the trial product at the selected dose level based on the results of the dose escalation phase. The dose expansion phase will further assess the safety and tolerability of the selected dose, and evaluate its initial anti-tumor activity under the same overall disease population and the same primary inclusion criteria. |
After being enrolled, the participants underwent tumor biopsy/ resection and then an Ommaya reservoir was implanted into the tumor. The participants would receive single-agent treatment with YSCH-01 every 3 weeks. YSCH-01 was administered within the tumor through the implanted Ommaya reservoir.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLT)
大体时间:21 days after the first dose and 21 days after the second dose
|
During the DLT observation period following the administration of YSCH-01, the incidence of DLTs will be evaluated. The occurrence of DLTs will be determined according to the criteria specified in the protocol |
21 days after the first dose and 21 days after the second dose
|
|
Safety and tolerability assessed by Adverse Events (AEs)
大体时间:From first dose up to 28 days after last dose
|
The incidence, severity, seriousness, and relationship to YSCH-01 of adverse events (AEs) will be assessed. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) 2018 consensus grading criteria. All other AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. Adverse events will be characterized by type, severity grade, seriousness, relationship to the investigational product, and outcome |
From first dose up to 28 days after last dose
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:From the first dose to 1 year post first dose
|
The time from the first dose to death from any cause |
From the first dose to 1 year post first dose
|
|
Progression-free survival (PFS)
大体时间:From the first dose to the date of documented disease progression or death from any cause, whichever occurs first, assessed for up to 6 months
|
To evaluate progression-free survival per Response Assessment in Neuro-Oncology (RANO) , version 2.0 criteria |
From the first dose to the date of documented disease progression or death from any cause, whichever occurs first, assessed for up to 6 months
|
|
Viral Biodistribution of YSCH-01 in Blood
大体时间:Baseline (within 2 hours before the first dose); 2, 4, 6, 24, 72, and 168 hours post first dose; predose and 2, 6, and 24 hours post the second to fifth dose; end of treatment (up to 1 year); 28 days after the last dose
|
Viral DNA levels of YSCH-01 in blood will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate the biodistribution of YSCH-01 Unit of Measure: Copies/μg DNA |
Baseline (within 2 hours before the first dose); 2, 4, 6, 24, 72, and 168 hours post first dose; predose and 2, 6, and 24 hours post the second to fifth dose; end of treatment (up to 1 year); 28 days after the last dose
|
|
Viral DNA Shedding of YSCH-01 in Feces
大体时间:Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
|
Viral DNA levels of YSCH-01 in feces samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment Unit of Measure: Copies/μg DNA |
Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
|
|
Viral DNA Shedding of YSCH-01 in Urine
大体时间:Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
|
Viral DNA levels of YSCH-01 in urine samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment Unit of Measure: Copies/reaction |
Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
|
|
Viral DNA Shedding of YSCH-01 in Nasopharyngeal Fluid
大体时间:Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
|
Viral DNA levels of YSCH-01 in nasopharyngeal fluid samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment Unit of Measure: Copies/reaction |
Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
|
|
Pharmacodynamic (PD): Serum IL-2 concentration
大体时间:Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
Serum IL-2 concentrations will be measured using the MSD assay Unit of Measure: pg/mL |
Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
|
PD: Serum IL-6 Concentration
大体时间:Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
Serum IL-6 concentrations will be measured using the MSD assay Unit of Measure: pg/mL |
Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
|
PD: Serum IL-8 Concentration
大体时间:Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
Serum IL-8 concentrations will be measured using the MSD assay Unit of Measure: pg/mL |
Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
|
PD: Serum IL-10 Concentration
大体时间:Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
Serum IL-10 concentrations will be measured using the MSD assay Unit of Measure: pg/mL |
Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
|
PD: Serum IL-12 concentration
大体时间:Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
Serum IL-12 concentrations will be measured using the MSD assay Unit of Measure: pg/mL |
Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
|
PD: Serum TNF-α concentration
大体时间:Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
Serum TNF-α concentrations will be measured using the MSD assay Unit of Measure: pg/mL |
Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
|
PD: Serum IFN-γ concentration
大体时间:Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
Serum IFN-γ concentrations will be measured using the MSD assay Unit of Measure: pg/mL |
Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
|
|
Anti-drug antibody (ADA) of adenovirus
大体时间:Pre-2 hours of each dose; at the end of treatment (up to 1 year)
|
Serum levels of anti-YSCH-01 antibodies will be measured by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Antibody levels will be reported in ng/mL Unit of Measure: ng/mL |
Pre-2 hours of each dose; at the end of treatment (up to 1 year)
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes of immune cell infiltration and the tumor microenvironment in paired tumor tissue samples
大体时间:At baseline surgery and at post-treatment repeat surgery, when available, within 1 year after the first dose
|
Paired tumor tissue samples collected at baseline and after treatment from participants undergoing repeat surgery will be analyzed to characterize changes in immune cell infiltration, immune cell populations, tumor immune microenvironment (TME) remodeling, and stromal composition following treatment |
At baseline surgery and at post-treatment repeat surgery, when available, within 1 year after the first dose
|
|
Cell-Free DNA (cfDNA) Levels in Cerebrospinal Fluid and Peripheral Blood
大体时间:At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available
|
Cell-free DNA (cfDNA) levels in cerebrospinal fluid (CSF), when available, and peripheral blood will be assessed using next-generation sequencing (NGS) or other validated molecular assays to explore their associations with treatment response |
At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available
|
|
Cytokine Profiles in Cerebrospinal Fluid
大体时间:At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available
|
Concentrations of IL-2, IL-6, IL-8, IL-10, IL-12, TNF-α, and IFN-γ in cerebrospinal fluid (CSF) will be measured using the MSD assay, consistent with the peripheral blood pharmacodynamic (PD) cytokine assessments. Each cytokine will be reported separately in pg/mL to explore treatment-related changes and their associations with treatment response Unit of Measure: pg/mL |
At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available
|
|
Absolute Counts of Immune Cell Populations in Cerebrospinal Fluid and Peripheral Blood
大体时间:At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available
|
Absolute counts of T cells, B cells, NK cells, and myeloid cells in cerebrospinal fluid (CSF) and peripheral blood will be characterized using flow cytometry. The absolute counts of each immune cell population will be reported separately in cells/mL to explore treatment-related changes and their associations with treatment response Unit of Measure: cells/mL |
At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- YSCH-01-CN002
- CTR20263831 (注册表标识符:China Drug Trials Registry (CTR))
- CXSL2501156 (其他标识符:CDE, NMPA China)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.